« Return to News | Study Conduct | Technology Solutions

CRF Health launches TrialMax Web for late-phase studies

Thursday, February 23, 2012 06:14 AM

CRF Health, a global provider of ePRO solutions, has launched TrialMax Web, an online ePRO and patient management solution for global late-phase clinical studies.

TrialMax Web combines PRO data capture and an array of tools to collect data directly from patients, who can use it on their own computers or smart phones. CRF Health hopes it will improve patient compliance and retention, critical challenges in late-phase research.

TrialMax Web eliminates the need for handling paper, making the collection of Patient Reported Outcomes both more cost efficient and more easily manageable for large studies. Study teams can utilize the data in real time according to the needs of the study.

“We believe that TrialMax Web offers an important new option for global phase IV study teams to interact with patients and deliver the highest quality data,” said Rachael King, CEO of CRF Health. 

Because TrialMax Web was developed as part of the TrialMax family of ePRO solutions, the portal is fully inter-operable with all of CRF Health’s other components. In addition, data can be transferred in real time to other eClinical systems, such as EDC via TrialMax Synapse, for greater efficiency.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.